Prudential PLC Has $17.55 Million Position in Pfizer Inc. $PFE

Posted by Francis Steltz on Jun 5th, 2026

Prudential PLC lowered its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 704,862 shares of the biopharmaceutical company’s stock after selling 88,665 shares during the period. Prudential PLC’s holdings in Pfizer were worth $17,551,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth $1,830,986,000. Bank of New York Mellon Corp grew its holdings in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after acquiring an additional 13,581,757 shares during the period. Franklin Resources Inc. grew its holdings in Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after acquiring an additional 8,108,887 shares during the period. Vanguard Group Inc. grew its holdings in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. Finally, Neuberger Berman Group LLC grew its holdings in Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer highlighted fresh oncology progress, including new and advancing clinical studies in lung cancer and bladder cancer, which could strengthen its long-term cancer pipeline if the early data continue to trend well. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
Positive Sentiment: The company also expanded its oncology pipeline with a new combination trial in advanced lung cancer, reinforcing the market’s view that cancer treatments remain a key growth area for Pfizer. Pfizer Expands Oncology Pipeline With New PF-08634404 Combo Trial in Advanced Lung Cancer
Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to use AI for drug discovery, signaling a push to speed up research and improve pipeline productivity over time. Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
Neutral Sentiment: Pfizer and Astellas advanced an early bladder cancer combination trial, which is encouraging scientifically but still too early to materially change near-term financial expectations. Pfizer and Astellas Advance New Bladder Cancer Combo in Early Clinical Trial
Neutral Sentiment: Pfizer’s conference presentation and several study updates on tofacitinib and bevacizumab biosimilars are incremental developments, but they are unlikely to move the stock on their own. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Negative Sentiment: Investor sentiment is still being weighed down by concerns that Pfizer is down about 4.5% since its last earnings report, suggesting the market remains focused on slower post-earnings momentum and earnings estimate pressure. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Analyst Upgrades and Downgrades

A number of research firms have commented on PFE. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.82.

Check Out Our Latest Research Report on PFE

Pfizer Trading Up 1.4%

Shares of NYSE PFE opened at $25.70 on Friday. The company’s fifty day moving average is $26.65 and its 200-day moving average is $26.29. The stock has a market cap of $146.46 billion, a price-to-earnings ratio of 19.62 and a beta of 0.34. Pfizer Inc. has a twelve month low of $23.08 and a twelve month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.